Short-term study of infliximab treatment for Crohn's disease in China

Journal of Digestive Diseases

Volumn 12, Issue 2, 2011, Pages 105-109

  Zheng, Jia Ju ^a   Zhi, Pang ^a   Wang, Yu Ming ^a   Zhu, Fan ^a   Gu, Wei ^a   Xing, Yi Chen ^a   Zhou, Chun Li ^a   Shen, Bi Wu ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Crohn's disease; Crohn's disease endoscopic index of severity; Harvey Bradshaw index; Infliximab

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; INFLIXIMAB;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLONOSCOPY; CROHN DISEASE; DRUG EFFECT; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HUMAN; LEUKOPENIA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; REMISSION; SHORT COURSE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHINA; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952668027     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2011.00485.x     Document Type: Article

References (17)

1. American Gastroenterological Association. American Gastroenterological Association consensus development conference of the use of biologics in the treatment of inflammatory bowel disease. Gastroenterology 2007; 133: 312-39.
2. Lémann M, Mary J-Y, Duclos B etal. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-61.
3. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-9.
4. Chinese Medical Association. A Consensus on diagnosis and management of inflammatory bowel disease in China. Chin J Dig 2007; 27: 545-50 (in Chinese).
5. Zheng J-j, Zhu X-s, Huang-fu Z, Shi X-h, Guo Z-r. Prevalence and incidence of Crohn's disease in mainland China: a meta-analysis of 55-year literatures. J Dig Dis 2009; 10 (Suppl 1): A67.
6. Wang YE, Ouyang Q, Hu RW. Progression of inflammatory bowel disease in China. J Diog Dis 2010; 11: 76-82.
7. Cilag AG Company. REMICADE (infliximab), Direction of Product Characteristics, 2007.2.15.
8. Hanauer SB, Fragan BG, Lichtenstein GR etal. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
9. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 315: 514-19.
10. Zheng J-J, Chu X-Q, Shi X-H, Zhou C-L, Shen B-W. Efficacy and safety of azathioprine maintenance therapy in a group of Crohn's disease patients in China. J Dig Dis 2008; 9: 84-8.
11. Mary JY, Modigliant R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Gut 1989; 30: 983-89.
12. Zheng J-j, Chu X-q, Shi X-h. Endoscopic indexes in gastrointestinal diseases. Chin J Gastroenterol 1999; 4: 256-7 (in Chinese).
13. van Dullemen HM, van Deventer SJH, Hommes DW etal. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
14. Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis 2007; 8: 171-8.
15. Mayer L, Han C, Bala M etal. Three dose induction regimen of infliximab (Remicade is superior to a single dose in patients with Crohn's disease CD). Am J Gastroenterol 2001; 96: S303.
16. Sandborn W, Targan S. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592-608.
17. Scholmerich J. Balancing the risks and benefits of prolonged use of infliximab. Gut 2009; 58: 477-8.